

Iris Lansdorp-Vogelaar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6911511/iris-lansdorp-vogelaar-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162
papers

8,620
citations

43
h-index

91
g-index

174
ext. papers

10,689
ext. citations

7.5
avg, IF

5.89
L-index

#	Paper	IF	Citations
162	Optimizing screening with faecal immunochemical test for both sexes - Cost-effectiveness analysis from Finland.. <i>Preventive Medicine</i> , 2022 , 106990	4.3	1
161	Risk-stratified strategies in population screening for colorectal cancer. <i>International Journal of Cancer</i> , 2022 , 150, 397-405	7.5	1
160	Socioeconomic differences in participation and diagnostic yield within the Dutch national colorectal cancer screening programme with faecal immunochemical testing.. <i>PLoS ONE</i> , 2022 , 17, e0264067	3.7	0
159	COVID-19 and Cancer Global Modelling Consortium (CCGMC): A global reference to inform national recovery strategies.. <i>Journal of Cancer Policy</i> , 2022 , 32, 100328	1	0
158	Urban density differences in colorectal cancer screening participation and screening yield in The Netherlands. <i>Preventive Medicine Reports</i> , 2022 , 27, 101791	2.6	
157	Colorectal Cancer Screening within Colonoscopy Capacity Constraints: Can FIT-Based Programs Save More Lives by Trading off More Sensitive Test Cutoffs against Longer Screening Intervals?. <i>MDM Policy and Practice</i> , 2022 , 7, 23814683221097064	1.5	0
156	A personalized and dynamic risk estimation model: The new paradigm in Barrett's esophagus surveillance.. <i>PLoS ONE</i> , 2022 , 17, e0267503	3.7	
155	Optimising colorectal cancer screening in Shanghai, China: a modelling study.. <i>BMJ Open</i> , 2022 , 12, e0481356	156	1
154	An Evolutionary Algorithm to Personalize Stool-Based Colorectal Cancer Screening.. <i>Frontiers in Physiology</i> , 2021 , 12, 718276	4.6	0
153	Comparative benefit and cost-effectiveness of mailed-out faecal immunochemical tests vs collection at the general practitioner. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1118-1125	6.1	
152	Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 ,	18.8	2
151	Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands.. <i>European Journal of Cancer</i> , 2021 , 161, 38-43	7.5	2
150	Modeling costs and benefits of the organized colorectal cancer screening programme and its potential future improvements in Hungary. <i>Journal of Medical Screening</i> , 2021 , 28, 268-276	1.4	4
149	Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1418-1425	6.9	9
148	Identifying key factors for the effectiveness of pancreatic cancer screening: A model-based analysis. <i>International Journal of Cancer</i> , 2021 , 149, 337-346	7.5	2
147	Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2021 , 50-51, 101735	2.5	4
146	Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening. <i>Value in Health</i> , 2021 , 24, 353-360	3.3	1

145	Measures of longitudinal adherence to fecal-based colorectal cancer screening: Literature review and recommended approaches. <i>International Journal of Cancer</i> , 2021 , 149, 316-326	7.5	1
144	Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 304-314	18.8	38
143	Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1998-2011	27.4	25
142	Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1730-1733	0.7	1
141	The impact of colorectal cancer screening on incidence and stage IV disease in the Netherlands.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3531-3531	2.2	
140	The EU-TOPIA evaluation tool: An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe. <i>Preventive Medicine Reports</i> , 2021 , 22, 101392	2.6	2
139	Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women. <i>JAMA Oncology</i> , 2021 , 7, 885-894	13.4	1
138	Colorectal Cancer Screening in Young Adults. <i>Annals of Internal Medicine</i> , 2021 , 174, 1039-1040	8	0
137	Calculation of Stop Ages for Colorectal Cancer Screening Based on Comorbidities and Screening History. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 547-555	6.9	7
136	Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 154-161	9.7	13
135	Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia. <i>Saudi Journal of Gastroenterology</i> , 2021 , 27, 208-216	3	3
134	The impact of information about different absolute benefits and harms on intention to participate in colorectal cancer screening: A think-aloud study and online randomised experiment. <i>PLoS ONE</i> , 2021 , 16, e0246991	3.7	1
133	Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study. <i>BMC Gastroenterology</i> , 2021 , 21, 67	3	0
132	Effects of cancer screening restart strategies after COVID-19 disruption. <i>British Journal of Cancer</i> , 2021 , 124, 1516-1523	8.7	23
131	Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration. <i>PLoS ONE</i> , 2021 , 16, e0253893	3.7	0
130	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	
129	Cost-effectiveness of prophylactic hysterectomy in first-degree female relatives with Lynch syndrome of patients diagnosed with colorectal cancer in the United States: a microsimulation study. <i>Cancer Medicine</i> , 2021 , 10, 6835-6844	4.8	1
128	The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic. <i>Preventive Medicine</i> , 2021 , 151, 106643	4.3	9

127	Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe. <i>MDM Policy and Practice</i> , 2021 , 6, 2381468320984974	1.5	2
126	The Impact of the Policy-Practice Gap on Costs and Benefits of Barrett's Esophagus Management. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1026-1035	0.7	1
125	Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. <i>European Journal of Cancer</i> , 2020 , 127, 224-235	7.5	47
124	Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2760-2767.e12	6.9	6
123	Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. <i>Gastroenterology</i> , 2020 , 158, 1274-1286.e12	13.3	47
122	The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening. <i>International Journal of Cancer</i> , 2020 , 147, 109841106	7.5	11
121	Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 10-21	4	14
120	Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1961-1969	6.9	11
119	Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe. <i>Journal of Medical Screening</i> , 2020 , 27, 68-76	1.4	8
118	Interpretation and adherence to the updated risk-stratified guideline for colonoscopy surveillance after polypectomy - a nationwide survey. <i>Endoscopy International Open</i> , 2020 , 8, E1405-E1413	3	
117	Intensity of Surveillance for Patients With Colorectal Adenomas. <i>Annals of Internal Medicine</i> , 2020 , 172, 442	8	
116	Validation of Colorectal Cancer Models on Long-term Outcomes from a Randomized Controlled Trial. <i>Medical Decision Making</i> , 2020 , 40, 1034-1040	2.5	4
115	Colorectal Cancer Screening in the Novel Coronavirus Disease-2019 Era. <i>Gastroenterology</i> , 2020 , 159, 1998-2003	13.3	7
114	Adherence to recommendations of Barrett's esophagus surveillance guidelines: a systematic review and meta-analysis. <i>Endoscopy</i> , 2020 , 52, 17-28	3.4	13
113	Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1493-1500	6.9	12
112	Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkz086	4.6	16
111	Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. <i>PLoS ONE</i> , 2019 , 14, e0220234	3.7	18
110	Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. <i>BMJ, The</i> , 2019 , 367, l5515	5.9	55

109	Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. <i>BMJ, The</i> , 2019 , 367, l5383	5.9	33
108	Trends in Incidence and Stage at Diagnosis of Colorectal Cancer in Adults Aged 40 Through 49 Years, 1975-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 1933-1934	27.4	32
107	Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. <i>Gut</i> , 2019 , 68, 1820-1826	19.2	220
106	Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis. <i>Gut</i> , 2019 , 68, 873-881	19.2	34
105	Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2019 , 123, 307-312	5.6	10
104	Yield of Surveillance Colonoscopies 1 Year After Curative Surgical Colorectal Cancer Resections. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2285-2293	6.9	3
103	Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 622-631	18.8	19
102	High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas: A Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2019 , 171, 612-622	8	7
101	Using Patient Preferences to Determine Noninferiority Margins in Trials. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 2137-2138	27.4	
100	Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 111-118	18.8	7
99	Quality Monitoring of a FIT-Based Colorectal Cancer Screening Program. <i>Clinical Chemistry</i> , 2019 , 65, 419-426	5.5	3
98	Colorectal Cancer: Cost-effectiveness of Colonoscopy versus CT Colonography Screening with Participation Rates and Costs. <i>Radiology</i> , 2018 , 287, 901-911	20.5	23
97	Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 1737-1744	4	8
96	Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. <i>Gastroenterology</i> , 2018 , 154, 556-567.e18	13.3	16
95	Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model. <i>BMC Cancer</i> , 2018 , 18, 464	4.8	11
94	Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria. <i>Gastrointestinal Endoscopy</i> , 2018 , 87, 397-404.e2	5.2	21
93	Stage distribution of screen-detected colorectal cancers in the Netherlands. <i>Gut</i> , 2018 , 67, 1745-1746	19.2	17
92	Summary statement on screening for prostate cancer in Europe. <i>International Journal of Cancer</i> , 2018 , 142, 741-746	7.5	19

91	Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer. <i>Gastroenterology</i> , 2018 , 154, 105-116.e20	13.3	14
90	Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 158-164	4	24
89	Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 504-512.e11	6.9	15
88	Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results. <i>Medical Decision Making</i> , 2018 , 38, 917-929	2.5	7
87	Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program. <i>Gastroenterology</i> , 2018 , 155, 1392-1399.e3	13.3	13
86	The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study. <i>PLoS ONE</i> , 2018 , 13, e0202924	3.7	5
85	Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries. <i>Health Policy</i> , 2018 , 122, 1206-1211	3.2	6
84	Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline. <i>Cancer</i> , 2018 , 124, 2974-2985	6.4	44
83	The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. <i>Cancer</i> , 2018 , 124, 2964-2973	6.4	108
82	Attendance and diagnostic yield of repeated two-sample faecal immunochemical test screening for colorectal cancer. <i>Gut</i> , 2017 , 66, 118-123	19.2	21
81	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1471-1474	6.9	18
80	Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1397-1404.e7	6.9	40
79	Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1328-1336	4	12
78	Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?. <i>Gut</i> , 2017 , 66, 1262-1267	19.2	13
77	Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. <i>British Journal of Cancer</i> , 2017 , 116, 44-49	8.7	43
76	Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries. <i>Health Affairs</i> , 2017 , 36, 2151-2159	7	10
75	Colorectal cancer screening in Australia. <i>Lancet Public Health, The</i> , 2017 , 2, e304-e305	22.4	3
74	Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia. <i>Gastroenterology</i> , 2017 , 153, 1251-1259.e2	13.3	28

73	Impact of adenoma detection on the benefit of faecal testing vs. colonoscopy for colorectal cancer. <i>International Journal of Cancer</i> , 2017 , 141, 2359-2367	7.5	5
72	Fecal immunochemical test-based colorectal cancer screening: The gender dilemma. <i>United European Gastroenterology Journal</i> , 2017 , 5, 448-454	5.3	26
71	Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. <i>BMC Cancer</i> , 2017 , 17, 112	4.8	6
70	Integrating personalised genomics into risk stratification models of population screening for colorectal cancer. <i>Australian and New Zealand Journal of Public Health</i> , 2017 , 41, 3-4	2.3	3
69	Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels. <i>Gastroenterology</i> , 2017 , 152, 767-775.e2	13.3	121
68	Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. <i>Gastroenterology</i> , 2017 ,	13.3	3
67	Increasing Incidence of Colorectal Cancer in Adolescents and Young Adults Aged 15-39 Years in Western Australia 1982-2007: Examination of Colonoscopy History. <i>Frontiers in Public Health</i> , 2017 , 5, 179	6	43
66	Optimizing Patient Risk Stratification for Colonoscopy Screening and Surveillance of Colorectal Cancer: The Role for Linked Data. <i>Frontiers in Public Health</i> , 2017 , 5, 234	6	1
65	Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. <i>PLoS ONE</i> , 2017 , 12, e0172864	3.7	31
64	Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1771-1777	6.9	18
63	Nonbleeding adenomas: Evidence of systematic false-negative fecal immunochemical test results and their implications for screening effectiveness-A modeling study. <i>Cancer</i> , 2016 , 122, 1680-8	6.4	15
62	Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1445-1451.e8	6.9	57
61	Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 2595-609	27.4	271
60	Different modalities for colorectal cancer screening: experiences in The Netherlands so far. <i>Colorectal Cancer</i> , 2016 , 5, 9-19	0.8	0
59	Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications. <i>Medical Decision Making</i> , 2016 , 36, 604-14	2.5	43
58	Screening for gastric cancer in Western countries. <i>Gut</i> , 2016 , 65, 543-4	19.2	25
57	Calibrating Parameters for Microsimulation Disease Models: A Review and Comparison of Different Goodness-of-Fit Criteria. <i>Medical Decision Making</i> , 2016 , 36, 652-65	2.5	8
56	Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , 2016 , 176, 894-902	11.5	170

55	Rationale and design of the European Polyp Surveillance (EPoS) trials. <i>Endoscopy</i> , 2016 , 48, 571-8	3.4	59
54	Developing a score chart to improve risk stratification of patients with colorectal adenoma. <i>Endoscopy</i> , 2016 , 48, 563-70	3.4	7
53	Cost effectiveness of surveillance for GI cancers. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2016 , 30, 879-891	2.5	5
52	A restricted look at CRC screening: not considering annual stool testing as an option. <i>American Journal of Managed Care</i> , 2016 , 22, e270-4	2.1	
51	Family history and the natural history of colorectal cancer: systematic review. <i>Genetics in Medicine</i> , 2015 , 17, 702-12	8.1	70
50	Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1464-71.e4	6.9	27
49	Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. <i>Gut</i> , 2015 , 64, 1327-37	19.2	114
48	Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 2349-58	27.4	51
47	Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study. <i>Gut</i> , 2015 , 64, 1584-92	19.2	60
46	Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. <i>Cancer</i> , 2015 , 121, 2281-5	6.4	134
45	Assessment of a cancer screening program. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2015 , 29, 979-85	2.5	13
44	The value of models in informing resource allocation in colorectal cancer screening: the case of The Netherlands. <i>Gut</i> , 2015 , 64, 1985-97	19.2	46
43	Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness. <i>Gastroenterology</i> , 2015 , 149, 1425-37	13.3	56
42	The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions. <i>Medical Decision Making</i> , 2015 , 35, 726-33	2.5	4
41	Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection. <i>International Journal of Cancer</i> , 2015 , 136, 2864-74	7.5	13
40	Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening. <i>Medical Care</i> , 2015 , 53, 630-83.1	3.1	9
39	State disparities in colorectal cancer rates: Contributions of risk factors, screening, and survival differences. <i>Cancer</i> , 2015 , 121, 3676-83	6.4	10
38	Optimal colorectal cancer screening in states: low-income, uninsured populations: the case of South Carolina. <i>Health Services Research</i> , 2015 , 50, 768-89	3.4	13

37	The impact of stratifying by family history in colorectal cancer screening programs. <i>International Journal of Cancer</i> , 2015 , 137, 1119-27	7.5	8
36	An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. <i>Gastroenterology</i> , 2015 , 149, 577-85.e4; quiz e14-5	13.3	30
35	Colorectal cancer deaths attributable to nonuse of screening in the United States. <i>Annals of Epidemiology</i> , 2015 , 25, 208-213.e1	6.4	63
34	Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. <i>Annals of Internal Medicine</i> , 2014 , 161, 104-12	8	91
33	Utilization of surveillance after polypectomy in the medicare population--a cohort study. <i>PLoS ONE</i> , 2014 , 9, e110937	3.7	5
32	Optimising the expansion of the National Bowel Cancer Screening Program. <i>Medical Journal of Australia</i> , 2014 , 201, 456-61	4	30
31	A cost-effectiveness analysis of online, radio and print tobacco control advertisements targeting 25-39 year-old males. <i>Australian and New Zealand Journal of Public Health</i> , 2014 , 38, 270-4	2.3	11
30	Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 997-1006	4	54
29	The appropriateness of more intensive colonoscopy screening than recommended in Medicare beneficiaries: a modeling study. <i>JAMA Internal Medicine</i> , 2014 , 174, 1568-76	11.5	21
28	Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. <i>Annals of Internal Medicine</i> , 2014 , 160, 750-9	8	76
27	Cost-effectiveness of screening and treating <i>Helicobacter pylori</i> for gastric cancer prevention. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2013 , 27, 933-47	2.5	42
26	Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality. <i>Journal of the National Cancer Institute Monographs</i> , 2013 , 2013, 117-23	4.8	5
25	Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. <i>Gut</i> , 2013 , 62, 727-34	19.2	59
24	Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. <i>Annals of Internal Medicine</i> , 2013 , 159, 667-76	8	100
23	Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. <i>New England Journal of Medicine</i> , 2012 , 366, 687-96	59.2	1934
22	Contribution of screening and survival differences to racial disparities in colorectal cancer rates. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 728-36	4	124
21	Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. <i>Gastroenterology</i> , 2011 , 141, 1648-55.e1	13.3	93
20	Productivity savings from colorectal cancer prevention and control strategies. <i>American Journal of Preventive Medicine</i> , 2011 , 41, e5-e14	6.1	24

19	How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?. <i>Cancer</i> , 2011 , 117, 4166-74	6.4	27
18	Cost-effectiveness of colorectal cancer screening. <i>Epidemiologic Reviews</i> , 2011 , 33, 88-100	4.1	188
17	Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis. <i>American Journal of Roentgenology</i> , 2011 , 196, 816-23	5.4	89
16	Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. <i>Radiology</i> , 2011 , 261, 487-98	20.5	28
15	Clarifying differences in natural history between models of screening: the case of colorectal cancer. <i>Medical Decision Making</i> , 2011 , 31, 540-9	2.5	33
14	A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. <i>Medical Decision Making</i> , 2011 , 31, 530-9	2.5	81
13	Fecal occult blood testing when colonoscopy capacity is limited. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1741-51	9.7	57
12	Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database. <i>American Journal of Epidemiology</i> , 2011 , 174, 1140-6	3.8	69
11	State disparities in colorectal cancer mortality patterns in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1296-302	4	69
10	Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1238-52	9.7	109
9	Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. <i>Annals of Internal Medicine</i> , 2010 , 153, 368-77	8	60
8	Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. <i>Cancer</i> , 2010 , 116, 544-73	6.4	1399
7	Cost-effectiveness of colorectal cancer screening - an overview. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2010 , 24, 439-49	2.5	42
6	Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1412-22	9.7	138
5	At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. <i>International Journal of Cancer</i> , 2009 , 124, 1161-8	7.5	51
4	Response to the letter to the editor by Hassan et al.: The diminutive lesion versus the advanced adenoma: Which is the real target of CT colonography screening?. <i>International Journal of Cancer</i> , 2009 , 125, 1239-1240	7.5	
3	A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. <i>Cancer</i> , 2009 , 115, 2410-9	6.4	64
2	Individualizing colonoscopy screening by sex and race. <i>Gastrointestinal Endoscopy</i> , 2009 , 70, 96-108, 108.5-1-24	5.1	55

1 Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*, **2008**, 149, 659-69 8 420